featured
2023 Top Story in Oncology: Circulating Tumor DNA Analysis to Guide Adjuvant Therapy
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Tie J, Cohen JD, Lahouel K, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022;386(24):2261-2272.
- Lonardi S, Pietrantonio F, Tarazona Llavero N, et al. The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. Paper presented at: 2023 ESMO Congress; October 20-24, 2023; Madrid, Spain. Abstract LBA28.
- Kim Y, Kim N, Lee YJ, et al. Feasibility of longitudinal monitoring of whole blood-based circulating tumour DNA (ctDNA) in patients with endometrial cancer. Paper presented at: 2023 ESMO Congress; October 20-24, 2023; Madrid, Spain. Abstract 591P.
- Nakamura Y, Kotani D, Saori M, et al. Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): An updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan). Paper presented at: 2023 ESMO Congress; October 20-24, 2023; Madrid, Spain. Abstract 558MO.
- Day D, Starus A, Gebski V, et al. Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial. Paper presented at: 2023 ESMO Congress; October 2024, 2023; Madrid, Spain. Abstract 586P.